Ratings Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
5.135 ^USD	+6.76%		+11.15%	+18.59%

May. 02	Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02	Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's earnings growth outlook lacks momentum and is a weakness.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PUMA BIOTECHNOLOGY, INC.	+18.59%	232M	C+
MODERNA, INC.	+26.37%	44.96B	B-
IQVIA HOLDINGS INC.	-1.01%	42.65B	B
LONZA GROUP AG	+46.00%	41.85B	A
CELLTRION, INC.	-5.31%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B	B
BIO-TECHNE CORPORATION	+6.23%	12.75B	B+
MEDPACE HOLDINGS, INC.	+26.99%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes